Compare

Gilead Sciences/$GILD

1D1W1M3M6MYTD1Y5YMAX

About Gilead Sciences

Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
Ticker
$GILD
Sector
Health
Primary listing
NASDAQ
Employees
17,000

Gilead Sciences Metrics

BasicAdvanced
$208B
-
-$3.12
0.37
$3.25
1.96%

What the Analysts think about Gilead Sciences

Analyst ratings (Buy, Hold, Sell) for Gilead Sciences stock.
Analyst projections of the future price of Gilead Sciences stock.

Bulls say / Bears say

Underlying momentum is strong: third-quarter product sales excluding Veklury rose 16% year on year to $8.2 billion, and Gilead raised its full-year 2026 product-sales outlook to $31.0–$31.3 billion. (Gilead Sciences)
HIV prevention offers another growth leg: Yeztugo generated $305 million in third-quarter sales and remains on track for about $1 billion in 2026. A weekly oral version is under FDA review, with a decision expected in February 2027, and could broaden its appeal if approved. (Gilead Sciences, Gilead Sciences)
Trodelvy's approval for first-line metastatic triple-negative breast cancer expands its potential market, while third-quarter sales rose 42% to $506 million. That gives Gilead a growing oncology product alongside its HIV franchise. (Gilead Sciences, Gilead Sciences)
Biktarvy faces a substantial pricing headwind: Medicare's 2028 price is 38% below list, and Gilead expects the change and related effects across US channels to reduce 2028 revenue by about $1.5 billion. (Reuters)
Cell therapy remains under competitive pressure: sales fell 18% year on year to $355 million in the third quarter. Gilead expects the segment's decline to continue through 2026. (Gilead Sciences, The Motley Fool)
The acquisition push is weighing heavily on near-term finances: Gilead expects $12.4 billion in acquired research charges in 2026 and now forecasts a reported loss per share. Its cash balance also fell to $6.4 billion after substantial acquisition outflows. (Gilead Sciences)
Data summarised monthly by Lightyear AI. Last updated on 4 Nov 2026.

Gilead Sciences Financial Performance

Revenues and expenses
Income statement
AnnuallyQuarterly
2023
YoY growth
Revenue
Net income
Profit margin

Gilead Sciences Earnings Performance

Company profitability
Earnings per share
AnnuallyQuarterly
2020
2021
2022
2023
2024
Actual
Expected
Surprise
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.